Skip to main content

Advertisement

SpringerLink
Log in

Severe ulcerative colitis

  • Published:
Current Treatment Options in Gastroenterology Aims and scope Submit manuscript

Opinion statement

Patients with severe ulcerative colitis should be hospitalized and treated with intravenous corticosteroids for 7 to 10 days. Patients who fail to respond may be offered colectomy or rescue therapy with intravenous cyclosporine. Risks of cyclosporine therapy, including a 1% to 2% risk of death from opportunistic infection and a 50% failure rate after 6 months of follow-up, should be discussed with the patient. Because of the high rate of relapse, patients who elect to be treated with cyclosporine should receive overlapping therapy with prednisone, cyclosporine and azathioprine or 6-mercaptopurine. Azathioprine or 6-mercaptopurine should then be continued long-term for maintenance of remission.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Truelove SC, Witts LT: Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J 1955, 2:1041–1048.

    Article  PubMed  CAS  Google Scholar 

  2. Truelove SC, Jewell DP: Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974, 1:1067–1070.

    Article  PubMed  CAS  Google Scholar 

  3. Dickinson RJ, Ashton MG, Axon ATR, et al.: Controlled trial of intravenous hyperalimentation and total bowel rest as an adjunct to the routine therapy of ulcerative colitis. Gastroenterology 1980, 79:119–1204.

    Google Scholar 

  4. McIntyre PB, Powell-Tuck J, Wood SR, et al.: Controlled trial of bowel rest in the treatment of severe acute colitis. Gut 1986, 27:481–485.

    PubMed  CAS  Google Scholar 

  5. Dickinson RJ, O’Connor HJ, Pinder I, et al.: Double-blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of ulcerative colitis. Gut 1985, 8:1380–1384.

    Google Scholar 

  6. Chapman RW, Selby WS, Jewell DP: Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut 1986, 27:1210–1212.

    PubMed  CAS  Google Scholar 

  7. Mantzaris GJ, Hatzis A, Kontogiannis P, Tridaphyllou G: Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am J Gastroenterol 1984, 89:43–46.

    Google Scholar 

  8. Lichtiger S, Present DH, Kornbluth A, et al.: Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994, 330:1841–1845. This randomized, double blind, placebo controlled trial of intravenous cyclosporine reports a clinical response in 83% of patients treated with cyclosporine as compared with 0% of patients treated with placebo in the setting of severe steroid refractory ulcerative colitis.

    Article  PubMed  CAS  Google Scholar 

  9. Sternthal M, Kornbluth A, Lichtiger S, Present D: Toxicity associated with the use of cyclosporine in patients with inflammatory bowel disease (IBD). Gastroenterology 1996, 110:A1019. This abstract reports the toxicity associated with intravenous cyclosporine therapy in 111 patients with inflammatory bowel disease.

    Google Scholar 

  10. Stein R, Cohen R, Hanauer S: Complications during cyclosporine therapy for inflammatory bowel disease. Gastroenterology 1997, 112:A1096.

    Article  Google Scholar 

  11. Sandborn WJ: A critical review of cyclosporine therapy in inflammatory bowel disease. Inflamm Bowel Dis 1995, 1:48–63. This article comprehensively reviews the clinical pharmacology and the results of treatment with cyclosporine in patients with inflammatory bowel disease.

    Article  Google Scholar 

  12. Fernandez-Banares F, Bertran X, Esteve-Comas M, et al.: Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis. Am J Gastroenterol 1996, 91:2498–2499.

    PubMed  CAS  Google Scholar 

  13. Ramakrishna J, Langhans N, Calenda K, et al.: Combined use of cyclosporine and azathioprine or 6-mercaptopurine in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1996, 22:296–302.

    Article  PubMed  CAS  Google Scholar 

  14. Carbonnel F, Lavergne A, Lemann M, et al.: A safe and reliable tool for assessment of severity. Dig Dis Sci 1994, 39:1150–1157.

    Article  Google Scholar 

  15. Alemayehu G, Janerot G: Colonoscopy during an attack of severe ulcerative colitis is a safe procedure and of great value in clinical decision making. Am J Gastroenterol 1991, 86:187–190.

    PubMed  CAS  Google Scholar 

  16. Bousvaros A, Wang A, Leichtner AM: Tacrolimus (FK-506) treatment of fulminant colitis in a child. J Pediatr Gastroenterol Nutr 1996, 23:329–333.

    Article  PubMed  CAS  Google Scholar 

  17. D’Haens G, Lemmens L, Hiele M, et al.: Intravenous cyclosporine (CYA) monotherapy versus intravenous methylprednisolone (MP) monotherapy in severe ulcerative colitis: a randomized, double-blind controlled trial [abstract]. Gastroenterology 1998, 114:A963.

    Google Scholar 

  18. Svanoni F, Bonassi U, Bagnolo F, Caporuscio S: Effectiveness of cyclosporine A (CSA) in the treatment of refractory ulcerative colitis (UC) [abstract]. Gastroenterology 1998, 114:A1096.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Inflammatory Bowel Disease Clinic, Mayo Clinic, 200 First Street SW, 55905, Rochester, MN

    William J. Sandborn MD

Authors
  1. William J. Sandborn MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sandborn, W.J. Severe ulcerative colitis. Curr Treat Options Gastro 2, 113–118 (1999). https://doi.org/10.1007/s11938-999-0038-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-999-0038-x

Keywords

Search

Navigation